Tengion Files For $40.25M IPO

East Norriton, Pa.-based venture funded biotech Tengion Inc. has filed for a $40.25 million initial public offering. Piper Jaffray & Co. will serve as the lead underwriter. It plans to trade on the Nasdaq under ticker symbol TNGN. Tengion has raised more than $140 million in VC funding, from Oak Investment Partners, HealthCap, Johnson & Johnson Development Corp., Brookside Capital, Bain Capital Ventures, Quaker BioVentures, L Capital Partners, Deerfield Partners and Safeguard Scientifics. Tengion is a regenerative medicine company focused on replacement organs such as bladders.